The Cell Imaging and Microscopy Shared Resource (CIM) provides cellular imaging technologies and services to enhance the programmatic research objectives of the Winship Cancer Institute (Winship). It is centrally located in Winship and houses state-of-the-art technologies including point scanning confocal, live cell confocal, spectral confocal imaging, epifluorescence microscopy, and image processing and analysis. CIM services have supported numerous Winship programmatic initiatives that include cancer cell biology, biomarker development, cancer nanotechnology, tumor diagnostics, drug delivery, and molecular pharmacology. These interactions have resulted in high Impact publications, team science grants, and inter- and intra-programmatic collaborations. Winship members comprise 88% of total CIM usage, with overall usage increasing from 1533 hours in calendar year 2008 to 4332 hours in 2010. CIM personnel provide consultation on experimental setup, execution, and analysis to ensure optimal image acquisition and data analysis. This includes comprehensive training sessions and dally user assistance to ensure that technologies are properly utilized. Alt user image data are archived nightly onto NAS enterprise level RAID protected servers to provide secure data backup. The CIM is a Winship shared resource, and Winship is responsible for oversight, operations, budget, compliance, user fee collection, and employee relations. The CIM Director makes all day-to-day decisions with input from CIM personnel, users, an internal advisory board, and executive oversight committee. The primary objectives of the CIM over the next two years are to expand small animal fluorescence imaging resources, implement a new assay development service, and continue to expand our IT infrastructure. These new technologies along with existing CIM services will enhance Winship's basic, translational, and clinical initiatives of Winship.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA138292-06
Application #
8634046
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
6
Fiscal Year
2014
Total Cost
$70,239
Indirect Cost
$25,214
Name
Emory University
Department
Type
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Greenwell, I Brian; Staton, Ashley D; Lee, Michael J et al. (2018) Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124:2306-2315
Hou, Yue; Konen, Jessica; Brat, Daniel J et al. (2018) TASI: A software tool for spatial-temporal quantification of tumor spheroid dynamics. Sci Rep 8:7248
Sadigh, Gelareh; Duszak Jr, Richard; Ward, Kevin C et al. (2018) Downstream Breast Imaging Following Screening Mammography in Medicare Patients with Advanced Cancer: A Population-Based Study. J Gen Intern Med 33:284-290
Patel, Mihir R; Hudgins, Patricia A; Beitler, Jonathan J et al. (2018) Radiographic Imaging Does Not Reliably Predict Macroscopic Extranodal Extension in Human Papilloma Virus-Associated Oropharyngeal Cancer. ORL J Otorhinolaryngol Relat Spec 80:85-95
Richardson, Alessandra M; Havel, Lauren S; Koyen, Allyson E et al. (2018) Vimentin Is Required for Lung Adenocarcinoma Metastasis via Heterotypic Tumor Cell-Cancer-Associated Fibroblast Interactions during Collective Invasion. Clin Cancer Res 24:420-432
Goldstein, Jordan S; Nastoupil, Loretta J; Han, Xuesong et al. (2018) Disparities in survival by insurance status in follicular lymphoma. Blood 132:1159-1166
Guidot, Daniel M; Switchenko, Jeffrey M; Nastoupil, Loretta J et al. (2018) Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility. Leuk Lymphoma 59:888-895
Jin, Lingtao; Chun, Jaemoo; Pan, Chaoyun et al. (2018) MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation. Cancer Cell 34:315-330.e7
Chowdhary, Mudit; Okwan-Duodu, Derick; Switchenko, Jeffrey M et al. (2018) Angiotensin receptor blockade: a novel approach for symptomatic radiation necrosis after stereotactic radiosurgery. J Neurooncol 136:289-298
Chen, Zhengjia; Zheng, Youyun; Wang, Zhibo et al. (2018) Interactive calculator for operating characteristics of phase I cancer clinical trials using standard 3+3 designs. Contemp Clin Trials Commun 12:145-153

Showing the most recent 10 out of 331 publications